secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001558370-25-000025
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Cyprium's NDA for CUTX-101 for priority review; action date June 30, 2025
--------------------------------------------------------------------------------

- FDA granted priority review to CUTX-101 (Copper Histidinate) NDA for treating Menkes disease.
- Target PDUFA action date is June 30, 2025; Sentynl (Zydus Group) will commercialize upon approval.
- Cyprium retains any Priority Review Voucher and is eligible for up to $129M in milestones plus royalties.
- Fortress Biotech owns ~76% of Cyprium, founded in 2017.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025000025/0001558370-25-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025000025/fbio-20250106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer